Plasma adrenomedullin and obstructive sleep apnea.
BACKGROUND
Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances.


METHODS
Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls.


RESULTS
Baseline ADM levels were similar in the OSA and control groups (28.7 +/- 6.7 v 27.7 +/- 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure.


CONCLUSIONS
OSA does not exert any significant acute or chronic effects on plasma ADM levels.
Wolk
Robert
R
Mayo Clinic, Rochester, Minnesota, USA.
Svatikova
Anna
A
Otto
Maria E
ME
Hoffmann
Michal S
MS
Duenwald
Carolyn J
CJ
Somers
Virend K
VK
D053607:Adrenomedullin; D000328:Adult; D015992:Body Mass Index; D045422:Continuous Positive Airway Pressure; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D017286:Polysomnography; D020181:Sleep Apnea, Obstructive / Q000097:blood* / Q000150:complications / Q000628:therapy
D010455:Peptides; D053607:Adrenomedullin